Alamar Biosciences Unveils New pTau Assays for Enhanced Neurodegenerative Disease Research

Alamar Biosciences, a pioneering company in precision proteomics, recently announced a significant expansion of its NULISAseq™ CNS Disease Panel 120 by integrating novel blood-based assays for brain-derived phosphorylated tau (pTau) proteins. This enhancement introduces pTau217, pTau181, pTau231, and total tau (tTau) proteins, all obtained directly from blood samples, which represents an unprecedented advancement in the field of neurodegenerative diseases.

Neurodegenerative diseases, such as Alzheimer’s and other tauopathies, have long posed challenges in early detection due to the complexities associated with biomarkers. Phosphorylated tau is crucial for early detection and ongoing monitoring of these conditions, and Alamar's latest panel aims to revolutionize this approach. Current assays tend to struggle with distinguishing between peripheral and central tau species, limiting their efficacy for precise diagnostics. However, with the upgraded CNS Disease Panel 120, researchers can now measure distinct brain-derived pTau species alongside peripheral tau forms, thus enabling a more comprehensive view of tau pathology.

Dr. Yuling Luo, CEO and Founder of Alamar Biosciences, emphasized the importance of these advancements by stating, "Researchers have long sought a reliable, blood-based solution to track brain-derived tau pathology. The integration of these assays empowers scientists to explore the full spectrum of tau pathology with exceptional sensitivity and throughput. This development is poised to accelerate biomarker-driven research and drug development targeting Alzheimer's disease and related neurodegenerative disorders."

The ability to detect brain-derived pTau proteins directly from blood is a transformative breakthrough. Nicholas Ashton, Ph.D., Director of Neurodegenerative Biomarker Research at Banner Health, noted, "Until now, we've been unable to differentiate between brain-derived and peripheral pTaus in a multiplexed manner. The new CNS panel from Alamar offers an unprecedented opportunity to enhance diagnostic accuracy and clinical utilities of these biomarkers, dramatically impacting patient care and research outcomes."

Alamar Biosciences is dedicated to facilitating advancements in neuroscience by partnering with researchers and clinicians to unlock essential biomarker insights. This collaboration enables earlier diagnosis, targeted patient stratification, and effective therapeutic monitoring.

For further information about the NULISAseq CNS Disease Panel 120 and Alamar Biosciences' full range of proteomic solutions, interested parties are encouraged to visit www.alamarbio.com.

About Alamar Biosciences

Alamar Biosciences operates as a privately held life sciences company with a bold mission: to harness the power of precision proteomics to enable the earliest detection of diseases. Utilizing the proprietary NULISA Platform alongside the ARGO™ HT System, Alamar Biosciences achieves incredible attomolar detection sensitivity. This level of sensitivity surpasses existing protein detection technologies on the market, allowing for more precise diagnostics and earlier interventions.

Through innovation and commitment to scientific excellence, Alamar Biosciences continues to lead the charge in advancing neurodegenerative disease research and ensuring health care professionals can provide the best possible outcomes for their patients.